Biomedical Technology

Bio-Cancer Treatment International Limited

🌍 Official Website 🏢 HKSTP Source
48 Potential

Decision Maker

Dr. Wolf Cheung
wcheung@bio-cancer.com
+852 3126 1566
Unit 302, Building 20E, No. 20 Science Park Eest Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong Hong Kong
Raw Description
Product | BCT’s product candidate portfolio comprises BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1). They are arginine depleting agents that retard tumour growth and ultimately lead to cancer death. BCT-100 is currently in phase I clinical trial in the US for the treatment of arginine-auxotrophic solid cancers and phase II clinical trial in the United Kingdom for the treatment of acute myeloid leukaemia (AML), in combination with low dose cytarabine, in elderly patients and in sarcomas, AML and neuroblastoma in paediatric patients. || BCT, founded in 2000, is a clinical-stage biopharmaceutical company. | Description | We develop innovative bio-therapeutics for safe and effective treatment of multiple cancer indications and auto-immune disorders

Strategic Analysis

Executive Brief

Bio-Cancer Treatment International Limited (BCT) is a clinical-stage biopharmaceutical company specializing in metabolic cancer therapies. Their primary innovation involves using pegylated recombinant human arginase 1 (BCT-100 and BCT-200) to deplete arginine, effectively starving arginine-auxotrophic tumors. They are currently managing complex Phase I and II clinical trials across the US and UK, focusing on solid tumors, AML, and pediatric cancers.

Strategic Fit & Lead Score

Lead Score: 48 (General Research / Engineering)

Why this Score? While BCT is a drug development firm and not a semiconductor or hardware manufacturer, their path to commercialization requires advanced analytical sensing and high-purity process environments. 6C’s diamond technology offers a significant "force multiplier" for their R&D and quality control departments, specifically through Boron-Doped Diamond (BDD) for metabolic sensing and Single Crystal Diamond (SCD) for high-resolution cellular imaging.

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Metabolic Monitoring BDD Electrochemical Sensors Boron-Doped Diamond electrodes allow for real-time, label-free detection of arginine and other metabolites in complex bio-fluids with zero electrode fouling.
High-Res Bio-Imaging SCD Optical Windows Ultra-pure Single Crystal Diamond (Ra < 1nm) provides the highest thermal conductivity and UV-IR transparency for laser-based observation of drug-cell interactions.
Quantum Diagnostics NV-Center SCD Enabling Nitrogen-Vacancy (NV) centers in diamond for nano-scale thermometry and magnetic field sensing within cell cultures to track metabolic changes induced by BCT-100.
Process Water Sterilization BDD Electrodes for EAOP Electrochemical Advanced Oxidation Processes (EAOP) using BDD can eliminate organic contaminants and ensure 9N-level purity in pharmaceutical process water without chemical additives.
Custom R&D Systems MPCVD Reactor Build Allows BCT’s research partners to develop custom diamond-coated microfluidic "Lab-on-a-Chip" devices for high-throughput screening of arginine-depletion efficacy.

Engagement Hooks

  • Technical Question: "As BCT-100 moves through Phase II trials, how is your team addressing the challenge of sensor fouling and signal drift when monitoring real-time arginine depletion levels in protein-rich clinical samples?"
  • Value Statement: "6C's proprietary MPCVD diamond surfaces provide an unmatched bio-inert platform for electrochemical sensing, ensuring that your metabolic data remains precise even in the most challenging biological environments."